Yüklüyor......
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients. However, a small proportion of patients initially r...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
National Academy of Sciences
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4183279/ https://ncbi.nlm.nih.gov/pubmed/25201956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1409362111 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|